Tag Archives: blockbuster

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Amarin has been on a scorching run with its fish-oil derivative Vascepa after a major cardiovascular outcomes trial last year set a possible blockbuster trajectory for the drug. Now, the FDA has voted to give Vascepa a major label boost with the addition of CV risk reduction––and those blockbuster sales could be on the near horizon. … Read More »

J&J’s Darzalex pads blockbuster sales with another myeloma nod in new patients

Johnson & Johnson multiple myeloma drug Darzalex hasn’t stopped rolling since hitting the market. After picking up its first nod in previously untreated patients last May, the drug added a second indication in new patients on Thursday—and its sixth overall. The FDA cleared the product in combination with Celgene’s Revlimid and dexamethasone for patients who… Read More »